MDxHealthMDXH
About: MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Employees: 312
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
58% more capital invested
Capital invested by funds: $30.1M [Q1] → $47.6M (+$17.5M) [Q2]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0.61% more ownership
Funds ownership: 42.9% [Q1] → 43.51% (+0.61%) [Q2]
0% more funds holding
Funds holding: 21 [Q1] → 21 (+0) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for MDXH.
Financial journalist opinion
